FDA 503A Peptide Review Tracker (2024-2026)

The FDA’s 503A peptide review tracker records which peptides a state-licensed compounding pharmacy may legally prepare for an individual patient—and which ones the agency now considers off-limits. Under Section 503A, a pharmacy can only compound a peptide if it is made from an FDA-approved ingredient, is not on the agency’s “do-not-compound” list, and is prescribed for a specific patient. Because these reviews change every few months, checking the tracker before you fill or refill a compounded peptide prescription is the fastest way to avoid delays or counterfeit products.

• The FDA must rule on every bulk peptide nominated before November 2013 by July 28, 2026, under the Drug Quality and Security Act timeline. [coldchaincheck.com]
• As of May 2026, 44 peptides have formal 503A decisions: 19 in Category 1 (generally permitted), 11 in Category 3 (pending), and 14 rejected for safety or efficacy concerns. [peptidejournal.org]
• Compounded semaglutide and tirzepatide remain allowable when sourced from FDA-approved ingredients and tied to a named patient prescription. [peptidemark.com]
• Most warning letters since 2024 target online sellers advertising research-grade peptides like retatrutide or mazdutide without a prescription. [fda.gov]
• Patients paying cash typically spend $185–$290 for a four-week vial of compounded semaglutide, versus $950+ for the brand. (Use Rx.com to compare prices.)

What Section 503A Means for Peptide Patients

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) is the federal law that lets a state-licensed pharmacy compound a medication—such as a peptide—only for a specific patient and only from FDA-approved ingredients. If those conditions are met, the pharmacy does not need the usual new-drug approval. The trade-off is strict limits: the peptide cannot mimic a commercial product that is readily available, cannot use bulk substances the FDA has rejected, and must follow state pharmacy-board rules. [fda.gov]

503A compounding is… the traditional “mom-and-pop” model: your pharmacist makes a custom product after receiving a valid prescription from your doctor. Because the batch is patient-specific, the pharmacy is exempt from facility registration and routine FDA inspection, unlike larger 503B outsourcing facilities.

How the FDA Reviews Peptides Under 503A

Every nominated bulk peptide ends up in one of three buckets—Category 1 (temporarily acceptable), Category 2 (unsafe), or Category 3 (still under review). The FDA evaluates:

Ingredient origin: Only USP-grade or FDA-approved active pharmaceutical ingredients (APIs) are acceptable.
Safety & efficacy data: The agency reviews published trials, adverse-event reports, and whether the peptide is similar to an approved drug.
Commercial availability: If an FDA-approved product already exists, 503A pharmacies can only compound it during a documented drug shortage.

The agency posts decisions to the 503A Bulks List docket each quarter. When the final rule publishes in 2026, any Category 3 peptides not promoted to Category 1 will automatically become prohibited for 503A compounding. [coldchaincheck.com]

Which Peptides Are Still Allowed?

Right now, your pharmacist can still compound several high-demand peptides, provided they source an FDA-approved API and label the vial properly. Examples include:

Patients interested in hair or skin healing often ask about GHK-Cu, but its pending status means availability could disappear overnight. For weight loss, compounded options like compounded tirzepatide or other GLP-1 peptides remain viable today.

Recent FDA Enforcement Actions (2024-2026)

Since 2024, the FDA has stepped up warning letters and import alerts targeting companies that sell peptides as “research chemicals” or ship large volumes without patient prescriptions.

The common thread is marketing before medicine—firms advertise investigational peptides or fail to restrict sales to licensed practitioners. If your vial came from one of these companies, stop using it and ask your pharmacist for documentation.

How to Protect Your Prescription Access

Know your peptide’s category: Check the FDA docket or this tracker before each refill. If your peptide slips from Category 1 to “rejected,” pharmacies must discontinue it immediately.

Ask for lot-specific COAs: Legitimate compounding pharmacies provide a certificate of analysis showing the peptide came from an FDA-registered manufacturer.

Confirm temperature control: Many peptides, including semaglutide, degrade above 46 °F. If shipping requires ice packs, verify arrival temperature. See our guide on what happens when a GLP-1 gets warm.